Cargando…

Point and Interval Estimators of the Target Dose in Clinical Dose-Finding Studies with Active Control

In a clinical dose finding study with active control a new drug with several dose levels is compared with an active comparator drug. The main focus of such studies often lies on the estimation of a target dose that leads to the same efficacy as the control. This article investigates the finite sampl...

Descripción completa

Detalles Bibliográficos
Autores principales: Helms, H.-J., Benda, N., Friede, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4566885/
https://www.ncbi.nlm.nih.gov/pubmed/24918730
http://dx.doi.org/10.1080/10543406.2014.920343
_version_ 1782389741444923392
author Helms, H.-J.
Benda, N.
Friede, T.
author_facet Helms, H.-J.
Benda, N.
Friede, T.
author_sort Helms, H.-J.
collection PubMed
description In a clinical dose finding study with active control a new drug with several dose levels is compared with an active comparator drug. The main focus of such studies often lies on the estimation of a target dose that leads to the same efficacy as the control. This article investigates the finite sample properties of the maximum likelihood estimation of the target dose and compares several approaches for constructing corresponding confidence intervals under the assumption of a linear dose-response curve and normal error terms. Furthermore, the impact of deviations from the model assumptions regarding the error distribution is explored.
format Online
Article
Text
id pubmed-4566885
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-45668852015-09-29 Point and Interval Estimators of the Target Dose in Clinical Dose-Finding Studies with Active Control Helms, H.-J. Benda, N. Friede, T. J Biopharm Stat Original Articles In a clinical dose finding study with active control a new drug with several dose levels is compared with an active comparator drug. The main focus of such studies often lies on the estimation of a target dose that leads to the same efficacy as the control. This article investigates the finite sample properties of the maximum likelihood estimation of the target dose and compares several approaches for constructing corresponding confidence intervals under the assumption of a linear dose-response curve and normal error terms. Furthermore, the impact of deviations from the model assumptions regarding the error distribution is explored. Taylor & Francis 2015-09-03 2014-06-11 /pmc/articles/PMC4566885/ /pubmed/24918730 http://dx.doi.org/10.1080/10543406.2014.920343 Text en Published with license by Taylor & Francis This is an Open Access article. Non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly attributed, cited and is not altered, transformed, or built upon in any way, is permitted. The moral rights of the named authors have been asserted.
spellingShingle Original Articles
Helms, H.-J.
Benda, N.
Friede, T.
Point and Interval Estimators of the Target Dose in Clinical Dose-Finding Studies with Active Control
title Point and Interval Estimators of the Target Dose in Clinical Dose-Finding Studies with Active Control
title_full Point and Interval Estimators of the Target Dose in Clinical Dose-Finding Studies with Active Control
title_fullStr Point and Interval Estimators of the Target Dose in Clinical Dose-Finding Studies with Active Control
title_full_unstemmed Point and Interval Estimators of the Target Dose in Clinical Dose-Finding Studies with Active Control
title_short Point and Interval Estimators of the Target Dose in Clinical Dose-Finding Studies with Active Control
title_sort point and interval estimators of the target dose in clinical dose-finding studies with active control
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4566885/
https://www.ncbi.nlm.nih.gov/pubmed/24918730
http://dx.doi.org/10.1080/10543406.2014.920343
work_keys_str_mv AT helmshj pointandintervalestimatorsofthetargetdoseinclinicaldosefindingstudieswithactivecontrol
AT bendan pointandintervalestimatorsofthetargetdoseinclinicaldosefindingstudieswithactivecontrol
AT friedet pointandintervalestimatorsofthetargetdoseinclinicaldosefindingstudieswithactivecontrol